Elan seeks new Tysabri usage

ELAN, the Irish drugmaker that reintroduced its Tysabri treatment for multiple sclerosis in July, is seeking US approval for its use in Crohn’s disease.

Elan and partner Biogen Idec have submitted a supplemental biologics licence application to the US Food and Drug Administration to use Tysabri in moderate to severe Crohn’s disease.